Literature DB >> 1834015

Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex.

C Truffot-Pernot1, B Ji, J Grosset.   

Abstract

Employing 7H11 agar medium at pH 6.6, the MICs of clarithromycin for 50% (MIC50) and 90% (MIC90) of 19 strains of Mycobacterium avium complex were 8 and 16 micrograms/ml, respectively. However, the MICs were 2 to 3 log2 dilutions lower in the 7H11 medium adjusted to pH 7.4, and the MICs on 10% OADC (oleic acid-albumin-dextrose-catalase)-enriched Mueller-Hinton agar at pH 7.3 were also 2 log2 dilutions lower than those measured on 7H11 agar at pH 6.6. Therefore, clarithromycin is more active at a physiologic than at an acidic pH.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1834015      PMCID: PMC245242          DOI: 10.1128/AAC.35.8.1677

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex.

Authors:  S Naik; R Ruck
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin.

Authors:  A L Barry; C Thornsberry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

3.  In vitro and in vivo activities of clarithromycin against Mycobacterium avium.

Authors:  P B Fernandes; D J Hardy; D McDaniel; C W Hanson; R N Swanson
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

4.  In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

5.  Comparative in-vitro activity of twenty antimicrobial agents against clinical isolates of Mycobacterium avium complex.

Authors:  N Khardori; K Rolston; B Rosenbaum; S Hayat; G P Bodey
Journal:  J Antimicrob Chemother       Date:  1989-11       Impact factor: 5.790

6.  Effect of carbon dioxide and pH on susceptibility of Bacteroides fragilis group to erythromycin.

Authors:  S L Hansen; P Swomley; G Drusano
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

7.  Effect of pH on the activity of erythromycin against 500 isolates of gram-negative bacilli.

Authors:  V Lorian; L D Sabath
Journal:  Appl Microbiol       Date:  1970-11

8.  In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.

Authors:  P B Fernandes; R Bailer; R Swanson; C W Hanson; E McDonald; N Ramer; D Hardy; N Shipkowitz; R R Bower; E Gade
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

  8 in total
  30 in total

1.  In vitro susceptibility of Mycobacterium kansasii to clarithromycin.

Authors:  J Biehle; S J Cavalieri
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy.

Authors:  B Ji; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

Review 3.  Susceptibility testing of Mycobacterium avium complex isolates.

Authors:  L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

4.  A randomized comparison of two clarithromycin doses for treatment of Mycobacterium avium complex infections.

Authors:  B Dautzenberg; C Truffot-Pernot; J Hazebroucq; S Legris; C Guérin; C Begelman; G Guermonprez; M H Fievet; C Chastang; J Grosset
Journal:  Infection       Date:  1997 Jan-Feb       Impact factor: 3.553

Review 5.  Prevention of the selection of clarithromycin-resistant Mycobacterium avium-intracellulare complex.

Authors:  J Grosset; B Ji
Journal:  Drugs       Date:  1997       Impact factor: 9.546

6.  Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model.

Authors:  B Ji; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

7.  A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions.

Authors:  P S Skinner; S K Furney; M R Jacobs; G Klopman; J J Ellner; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

8.  Activity of clarithromycin against Mycobacterium avium complex infection in beige mice.

Authors:  S P Klemens; M S DeStefano; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

9.  Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages.

Authors:  Y Cohen; C Perronne; C Truffot-Pernot; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

10.  Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS.

Authors:  F de Lalla; R Maserati; P Scarpellini; P Marone; R Nicolin; F Caccamo; R Rigoli
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.